25% revenue growth in FY27
Management guided for 25% year-on-year revenue growth in FY27, consistent with historical performance.
ACUTAASCHEMICALS / guidance tracker
Keep management guidance in view.
Acutaas Chemicals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin similar to FY26 level
Management expects EBITDA margin to remain at similar levels as FY26 (around 35-36%), driven by product mix.
CDMO revenue target of ₹1,000 cr by FY28
The CDMO business is expected to reach ₹1,000 cr in revenue by FY28, backed by long-term contracts and pipeline.
Capex of ~₹90 cr in FY27 (spillover + maintenance)
FY27 capex includes ~₹50 cr spillover from FY26 (electrolyte additive and pilot plant) and ~₹40 cr maintenance capex.